



ABN: 97 084 464 193

Traverse Accountants
Pty Ltd, Suite 404
Level 4 , 25 Lime
Street, Sydney NSW
2000

P: +61 2 8296 0000



**Australian Securities Exchange Limited
Companies Announcements Office
SYDNEY**

12 February 2013

BIOXYNE APPOINTS NEW COMPANY SECRETARY

Bioxyne Limited (ASX: BXN or the Company) announces the appointment of Mr Jarrod White as Company Secretary. Jarrod is a director at Traverse Accountants.

For Further information please contact:

Dr. Phillip Comans
Chief Executive Officer
Bioxyne Limited
Mobile: +61 439 466 116

www.bioxyne.com

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company's lead therapy, HI-164OV is based on the Company's proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV works by controlling bacterial infections of airways damaged by toxins. The global incidence of COPD, which includes common

diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets. Bioxyne also makes and sells consumer food supplements, based on



ABN: 97 084 464 193

Traverse Accountants
Pty Ltd, Suite 404
Level 4 , 25 Lime
Street, Sydney NSW
2000

P: +61 2 8296 0000



a proprietary probiotic compound, generating a source of revenues. For further information please visit www.bioxyne.com

COPD

Chronic Obstructive Pulmonary Disease (COPD) is a disease largely caused by smoking but with a rising number of new cases caused by pollution in developing countries like China and India. The global demand for COPD treatments is growing rapidly with an analysis by the Australian Lung Foundation in 2008 indicating the wide economic cost of to the Australian economy in 2010 was estimated to be \$9 billion in direct and indirect costs, with \$1 billion incurred in direct health system expenditure. There are currently no effective treatments for COPD and 25 per cent of COPD patients admitted to hospital die within one year. Reducing hospital admissions is crucial and preventing exacerbations is the main choice of therapy. More than 15 per cent of new patients have never smoked and

Industrial pollution is viewed as a major risk factor in the onset of COPD. It is estimated COPD will be third leading cause of mortality in the next decade, behind heart failure and cancer.